Tests:Cholesterol-HDL Ratio, Plasma: Difference between revisions

Tests:Cholesterol-HDL Ratio, Plasma
No edit summary
No edit summary
Line 4: Line 4:
{| class="wikitable"
{| class="wikitable"
! colspan="2" |
! colspan="2" |
===''Overview''===
== Overview ==
|-
|-
|Department
|Department
Line 14: Line 14:
|Synonyms
|Synonyms
|Lipid profile 
|Lipid profile 
|-
|Test Availabilty
|Monday - Sunday, testing routinely available out of hours
|-
|-
|Turnaround Time
|Turnaround Time
Line 22: Line 25:
|-
|-
! colspan="2" |
! colspan="2" |
===''Specimen Requirements''===
== Specimen Requirements ==
|-
|-
|Specimen Type
|Specimen Type
Line 33: Line 36:
|Acceptable
|Acceptable
|4 mL  Li-Hep <span style="background:#3cb371"> Green-Top </span>  
|4 mL  Li-Hep <span style="background:#3cb371"> Green-Top </span>  
|-
|Unacceptable
|
|-
|-
|Specimen Transportation
|Specimen Transportation
|
|
|-
|-
|Pediatric Requirements
|Paediatric Requirements
|600 µL <span style="background:#99e6b3"> Li-Hep Microtainer </span> Paediatric tube
|600 µL <span style="background:#99e6b3"> Li-Hep Microtainer </span>  
|-
|-
! colspan="2" |
! colspan="2" |
===''Aliquot Requirements''===
== Aliquot Requirements ==
|-
|-
|Sample Type
|Sample Type
|
|-
|Preferred Volume
|
|
|-
|-
Line 53: Line 62:
|-
|-
! colspan="2" |
! colspan="2" |
===''Clinical Information''===
== Clinical Information ==
|-
|-
|Reference Intervals
|Reference Intervals
Line 68: Line 77:
|-
|-
! colspan="2" |
! colspan="2" |
===''Comments''===
== Comments ==
|-
|-
| colspan="2" |Help for Lipid Studies Interpretation  
| colspan="2" |''Help for Lipid Studies Interpretation''


Reported Comments:  
Reported Comments:  


1. All reports get this comment (see below for additional information on optimal  
1. All reports get this comment (see below for additional information on optimal levels):  
 
levels):
 
"Optimal  levels are suggested by the New Zealand Guidelines Group though an  individualised multi-factorial approach is preferred."
 
2. All reports  get this comment, unless superseded by any
 
one or more of  the other comments below:  


"Cardiovascular risk should be  addressed by lifestyle and
"Optimal levels are suggested by the New Zealand Guidelines Group though an individualised multi-factorial approach is preferred."


pharmacological  interventions in subjects with 5-year CV risk
2. All reports get this comment, unless superseded by anyone or more of the other comments below:


greater than 15%."  
"Cardiovascular risk should be addressed by lifestyle and pharmacological interventions in subjects with 5-year CV risk greater than 15%."  


3. Total cholesterol >8 mmol/L or Total cholesterol/HDL ratio >8:
3. Total cholesterol >8 mmol/L or Total cholesterol/HDL ratio >8:
|}
|}